Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe

Tools

Raschi, Emanuel and Poluzzi, Elisabetta and Godman, Brian and Koci, Ariola and Moretti, Ugo and Kalaba, Marija and Bennie, Marion and Barbui, Corrado and Wettermark, Bjorn and Sturkenboom, Miriam and De Ponti, Fabrizio (2013) Torsadogenic risk of antipsychotics : combining adverse event reports with drug utilization data across Europe. PLOS One, 8 (11). e81208. ISSN 1932-6203 (https://doi.org/10.1371/journal.pone.0081208)

[thumbnail of journal.pone.0081208]
Preview
 PDF. Filename: journal.pone.0081208.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Antipsychotics (APs) have been associated with risk of torsade de Pointes (TdP). This has important public health implications. Therefore, (a) we exploited the public FDA Adverse Event Reporting System (FAERS) to characterize their torsadogenic profile; (b) we collected drug utilization data from 12 European Countries to assess the population exposure over the 2005-2010 period. FAERS data (2004-2010) were analyzed based on the following criteria: (1) ≥ 4 cases of TdP/QT abnormalities; (2) Significant Reporting Odds Ratio, ROR [Lower Limit of the 95% confidence interval>1], for TdP/QT abnormalities, adjusted and stratified (Arizona CERT drugs as effect modifiers); (3) ≥ 4 cases of ventricular arrhythmia/sudden cardiac death (VA/SCD); (4) Significant ROR for VA/SCD; (5) Significant ROR, combined by aggregating TdP/QT abnormalities with VA and SCD. Torsadogenic signals were characterized in terms of signal strength: from Group A (very strong torsadogenic signal: all criteria fulfilled) to group E (unclear/uncertain signal: only 2/5 criteria). Consumption data were retrieved from 12 European Countries and expressed as defined daily doses per 1,000 inhabitants per day (DID). Thirty-five antipsychotics met at least one criterium: 9 agents were classified in Group A (amisulpride, chlorpromazine, clozapine, cyamemazine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone). In 2010, the overall exposure to antipsychotics varied from 5.94 DID (Estonia) to 13.99 (France, 2009). Considerable increment of Group A agents was found in several Countries (+3.47 in France): the exposure to olanzapine increased across all Countries (+1.84 in France) and peaked 2.96 in Norway; cyamemazine was typically used only in France (2.81 in 2009). Among Group B drugs, levomepromazine peaked 3.78 (Serbia); fluphenazine 1.61 (Slovenia). This parallel approach through spontaneous reporting and drug utilization analyses highlighted drug- and Country-specific scenarios requiring potential regulatory consideration: levomepromazine (Serbia), fluphenazine (Slovenia), olanzapine (across Europe), cyamemazine (France). This synergy should be encouraged to support future pharmacovigilance activities.

ORCID iDs

Raschi, Emanuel, Poluzzi, Elisabetta, Godman, Brian, Koci, Ariola, Moretti, Ugo, Kalaba, Marija, Bennie, Marion ORCID logoORCID: https://orcid.org/0000-0002-4046-629X, Barbui, Corrado, Wettermark, Bjorn, Sturkenboom, Miriam and De Ponti, Fabrizio;
CORE (COnnecting REpositories)